Does Rallies show Form 4 insider transactions for CARL?

Yes. Rallies tracks CARL insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is CARL research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CARL. It does not provide personalized investment advice.

CARL (Carlsmed, Inc. Common Stock) Stock Analysis - Insider Trades

Carlsmed, Inc. Common Stock (CARL) is a publicly traded Healthcare sector company. As of May 21, 2026, CARL trades at $11.77 with a market cap of $297.13M and a P/E ratio of -5.59. CARL moved +4.07% today. Year to date, CARL is -2.65%; over the trailing twelve months it is flat. Its 52-week range spans $8.50 to $17.19. Analyst consensus is strong buy with an average price target of $18.40. Rallies surfaces CARL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading CARL stock inside the company?

Recent CARL insider activity includes Cordonnier Michael sold 197.85K, B CAPITAL GROUP MANAGEMENT, L.P. bought 1.33M, Sidow Kevin bought 13.33K, Mittendorff Robert II bought 1.33M, and ROOT JONATHAN D bought 466.67K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

CARL Key Metrics

Key financial metrics for CARL
Metric	Value
Price	$11.77
Market Cap	$297.13M
P/E Ratio	-5.59
EPS	$-2.12
Dividend Yield	0.00%
52-Week High	$17.19
52-Week Low	$8.50
Volume	0
Avg Volume	0
Revenue (TTM)	$50.51M
Net Income	$-29.63M
Gross Margin	75.31%

Recent CARL Insider Trades

Cordonnier Michael sold 197.85K (~$2.63M) on Mar 2, 2026.
B CAPITAL GROUP MANAGEMENT, L.P. bought 1.33M (~$20.00M) on Jul 24, 2025.
Sidow Kevin bought 13.33K (~$200.00K) on Jul 24, 2025.
Mittendorff Robert II bought 1.33M (~$20.00M) on Jul 24, 2025.
ROOT JONATHAN D bought 466.67K (~$7.00M) on Jul 24, 2025.

Latest CARL News

Carlsmed Posts 58% Revenue Growth, Raises 2026 Guidance to $72–77M — May 5, 2026
Carlsmed Forecasts 44% Growth to $70–75.5M, Posts Q4 Revenue Above $15M — Mar 7, 2026
Carlsmed Sees Record Q4 2025 Revenue, Emphasizes Cost Cuts and Pipeline — Feb 26, 2026
Carlsmed Sees 61% Q4 Revenue Growth to $15.2M, Guides $70M-$75M for 2026 — Feb 25, 2026
Carlsmed Completes First Patient-Specific corra™ Cervical Plating Procedure, Eyes 2026 Launch — Feb 18, 2026

CARL Analyst Consensus

5 analysts cover CARL: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $18.40.

Common questions about CARL

Who is trading CARL stock inside the company?: Recent CARL insider activity includes Cordonnier Michael sold 197.85K, B CAPITAL GROUP MANAGEMENT, L.P. bought 1.33M, Sidow Kevin bought 13.33K, Mittendorff Robert II bought 1.33M, and ROOT JONATHAN D bought 466.67K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for CARL?: Yes. Rallies tracks CARL insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is CARL research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CARL. It does not provide personalized investment advice.